The objective of this grant application is to become one of the core clinical centers in the proposed Blood and Marrow Transplant Clinical Research Network. There are a number of features of the Fred Hutchinson Cancer Research Center (FECRC) Marrow Transplant Program that make it an attractive candidate for inclusion in the Network. First, we have maintained a large, stable transplant program for several decades transplanting between 450 and 550 patients per year with excellent clinical outcomes. Thus, we have access to a relatively large number of patients. Second, our group includes a large number of investigators focused on the general topic of transplantation. This group is supported by seven P0ls and 23 R0ls, and last year published 142 papers on the topic. Thus, our inclusion will help assure a source of possible studies for future testing in the Transplant Network. Third, our program is deeply committed to cooperative clinical research. For example, last year 231 of 451 patients transplanted in Seattle (51%) were entered onto multi-institutional trials. Finally, the FHCRC provides an outstanding environment in which to conduct the sorts of studies described, with state-of-the-art clinical and laboratory facilities. The proposed Blood and Marrow Transplant Clinical Research Network has the potential to facilitate studies leading to substantial improvements in the outcome of transplantation. Inclusion of the Fred Hutchinson Cancer Research Center in this network should help it achieve this goal.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01HL069246-05
Application #
7098008
Study Section
Special Emphasis Panel (ZHL1-CSR-F (S1))
Program Officer
Di Fronzo, Nancy L
Project Start
2002-06-05
Project End
2006-09-28
Budget Start
2006-06-01
Budget End
2006-09-28
Support Year
5
Fiscal Year
2006
Total Cost
$334,229
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Wood, William A; Le-Rademacher, Jennifer; Syrjala, Karen L et al. (2016) Patient-reported physical functioning predicts the success of hematopoietic cell transplantation (BMT CTN 0902). Cancer 122:91-8
Knight, Jennifer M; Syrjala, Karen L; Majhail, Navneet S et al. (2016) Patient-Reported Outcomes and Socioeconomic Status as Predictors of Clinical Outcomes after Hematopoietic Stem Cell Transplantation: A Study from the Blood and Marrow Transplant Clinical Trials Network 0902 Trial. Biol Blood Marrow Transplant 22:2256-2263
Khera, Nandita; Majhail, Navneet S; Brazauskas, Ruta et al. (2015) Comparison of Characteristics and Outcomes of Trial Participants and Nonparticipants: Example of Blood and Marrow Transplant Clinical Trials Network 0201 Trial. Biol Blood Marrow Transplant 21:1815-22
Anderlini, Paolo; Wu, Juan; Gersten, Iris et al. (2015) Cyclophosphamide conditioning in patients with severe aplastic anaemia given unrelated marrow transplantation: a phase 1-2 dose de-escalation study. Lancet Haematol 2:e367-75
Jacobsen, Paul B; Le-Rademacher, Jennifer; Jim, Heather et al. (2014) Exercise and stress management training prior to hematopoietic cell transplantation: Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0902. Biol Blood Marrow Transplant 20:1530-6
Waller, Edmund K; Logan, Brent R; Harris, Wayne A C et al. (2014) Improved survival after transplantation of more donor plasmacytoid dendritic or naïve T cells from unrelated-donor marrow grafts: results from BMTCTN 0201. J Clin Oncol 32:2365-72
Wagner Jr, John E; Eapen, Mary; Carter, Shelly et al. (2014) One-unit versus two-unit cord-blood transplantation for hematologic cancers. N Engl J Med 371:1685-94
Tolar, Jakub; Deeg, H Joachim; Arai, Sally et al. (2012) Fludarabine-based conditioning for marrow transplantation from unrelated donors in severe aplastic anemia: early results of a cyclophosphamide dose deescalation study show life-threatening adverse events at predefined cyclophosphamide dose levels. Biol Blood Marrow Transplant 18:1007-11